Anzeige
Meldung des Tages: 150 Mio. USD für Compass – aber Optimi ist der wahre Gamechanger

Whitehawk Therapeutics Aktie News

Aktie
WKN:  A3CSR9 ISIN:  US00032Q1040 US-Symbol:  WHWK Branche:  Biotechnologie Land:  USA
3,14 $
+0,12 $
+3,97%
2,6616 € 24.02.26
Depot/Watchlist
Marktkapitalisierung *
56,02 Mio. €
Streubesitz
19,92%
KGV
-3,51
Index-Zuordnung
-

Whitehawk Therapeutics News

18.02.26 - PR Newswire
Whitehawk Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Whitehawk Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference PR Newswire
08.01.26 - PR Newswire
Whitehawk Therapeutics Advances to Clinical Stage with IND Clearance for HWK-007 and Announces IND Submission for HWK-016
Whitehawk Therapeutics Advances to Clinical Stage with IND Clearance for HWK-007 and Announces IND Submission for HWK-016 PR Newswire
01.12.25 - PR Newswire
Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer
Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer PR Newswire
26.11.25 - PR Newswire
Whitehawk Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
Whitehawk Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference PR Newswire
11.11.25 - PR Newswire
Whitehawk Therapeutics to Present at Jefferies Global Healthcare Conference in London
Whitehawk Therapeutics to Present at Jefferies Global Healthcare Conference in London PR Newswire
06.11.25 - PR Newswire
Whitehawk Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
Whitehawk Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights PR Newswire
24.10.25 - PR Newswire
Whitehawk Therapeutics Presents Real-World Analysis Confirming PTK7 as a Broadly Expressed, Clinically Relevant Target Across Solid Tumors at AACR-NCI-EORTC
Whitehawk Therapeutics Presents Real-​World Analysis Confirming PTK7 as a Broadly Expressed, Clinically Relevant Target Across Solid Tumors at AACR-​NCI-EORTC PR Newswire
02.09.25 - PR Newswire
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences PR Newswire
07.08.25 - PR Newswire
Whitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
Whitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights PR Newswire
22.07.25 - PR Newswire
Whitehawk Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
Whitehawk Therapeutics to Participate in the BTIG Virtual Biotechnology Conference PR Newswire
19.06.25 - PR Newswire
Whitehawk Therapeutics to Participate in H.C. Wainwright "HCW@Home" Series
Whitehawk Therapeutics to Participate in H.C. Wainwright "HCW@Home" Series PR Newswire
28.05.25 - PR Newswire
Whitehawk Therapeutics to Present at the Jefferies 2025 Global Healthcare Conference
Whitehawk Therapeutics to Present at the Jefferies 2025 Global Healthcare Conference PR Newswire
08.05.25 - PR Newswire
Whitehawk Reports First Quarter 2025 Financial Results and Recent Highlights
Whitehawk Reports First Quarter 2025 Financial Results and Recent Highlights PR Newswire
26.03.25 - PR Newswire
Whitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Pharmaceuticals
Whitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Pharmaceuticals PR Newswire
14.03.25 - PR Newswire
Aadi Bioscience to Report Fourth Quarter and Full-Year 2024 Results and Corporate Update
Aadi Bioscience to Report Fourth Quarter and Full-Year 2024 Results and Corporate Update PR Newswire
04.03.25 - PR Newswire
Aadi Bioscience Announces Closing of $100 Million PIPE Financing
Aadi Bioscience Announces Closing of $100 Million PIPE Financing PR Newswire
03.03.25 - PR Newswire
Aadi Bioscience Announces Approval of All Proposals at Special Meeting of Stockholders
Aadi Bioscience Announces Approval of All Proposals at Special Meeting of Stockholders PR Newswire

Newssuche

Videos

newspaper
18.02.26 +6,11%
Technical Trading: Chance mit 82 Prozent Treffern
Rohöl Long Typ: Turbo Open End WKN: VH65XQ Hebel:6 Laufzeit: OpenEnd Einstieg: Market ... Mehr »